9th Annual Biomarkers Congress

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2012 Cell Adhesion Molecules In Asthma and COPD: Basic Mechanisms and Clinical Management, P. Barnes, J. Drazen, S. Rennard, and N. Thomson, Editors, Academic Press, London, in press.
2. 2012 Identification of urine odor signatures in mouse models of lung cancer PLoS ONE, 5(1): e8819.
3. 2012 Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates J Control Release (in press).
4. 2010 Evaluation of an Attenuated Vesicular Stomatitis Virus (VSV) Vector expressing Interferon-b for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon-Responsiveness Defines Potential Efficacy Human Gene Therapy, 21: 51-64, 2010.
5. 2010 Gene Therapy for Malignant Pleural Mesothelioma In Gene-based Therapies for Cancer (Chapter 7), Current Cancer Research, J.A. Roth, Editor, Springer Science and Business Media, 2010
6. 2010 Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor Cancer Research, 70:9053-61, 2010
7. 2010 Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intra-tumoral oncolytic virus and cyclophosphamide. Mol. Therapy, in press.
8. 2010 Chemotherapy Delivered After Viral Immuno-Gene Therapy Augments Anti-tumor Efficacy via Multiple Immune-Mediated Mechanisms Mol. Therapy, 18:1947-59, 2010.
9. 2010 CCL2 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ Cells Am J. Respir. Cell Mol. Biol, 18:1947-59, 2010.
10. 2010 Preclinical evidence for a beneficial impact of valproate in response of small cell lung cancer to first-line chemotherapy European Journal of Cancer,46:1724-34, 2010
11. 2010 Advanced glycation endproducts on stored erythrocytes increase endothelial reactive oxygen species generation through interaction with RAGE Transfusion May 13- epub 2010
12. 2010 CCL2 blockade augments cancer immunotherapy. Cancer Res. 70:109-18. 2010.
13. 2010 Activation of the NOD Signaling Pathways by a Non-bacterially Derived, Small Molecule, 5'6-dimethylxanthenone-4-acetic acid J. Biologic Chemistry, 285:10553-10562, 2010.
14. 2010 Gene Therapy for Mesothelioma and Lung cancer Am. J. Resp. Cell and Molecular Biology., 42:385-393, 2010.
15. 2010 A Phase I Trial of Repeated Intrapleural Adenoviral-Mediated Interferon Beta Gene Transfer for Mesothelioma and Metastatic Pleural Effusion Molecular Therapy, 18:852-860, 2010.
16. 2009 Targeted detoxification of selected reactive oxygen species in the vascular endothelium J. of Pharm. and Exp. Therapeutics, 331(2):404-11, 2009.
17. 2009 Kinetics of Soluble Mesothelin Levels in Patients with Malignant Pleural Mesothelioma during Treatment. American Journal of Respiratory and Critical Care Medicine. 179: 950-954, 2009.
18. 2009 Control of large established tumor xenografts with genetically re-targeted human T cells containing CD28 and CD137 domains Proc. Natl. Acad. Sci., 106: 3360, 3365, 2009.
19. 2009 Anchoring Fusion thrombomodulin to the Endothelial Lumen Protects Injury-Induced Lung Thrombosis and Inflammation Am. J. of Respir. Crit. Care Medicine, 180:247-56, 2009.
20. 2009 Variation in the MYLK Gene is Associated with Development of Acute Lung Injury Following Major Trauma, Cancer Cell, 16:183-194, 2009.
21. 2009 The HDAC Inhibitor Panobinostat (LBH589) Inhibits Mesothelioma and Lung Cancer Cell Lines in vitro and in vivo with Particular Efficacy in Small Cell Lung Cancer Molecular Cancer Therapeutics, 8: 2221-2231, 2009.
22. 2009 Expression of IFN-β Enhances Both Efficacy and Safety of Oncolytic VSV for Therapy of Mesothelioma Cancer Research, 69:7713-20, 2009
23. 2009 Diagnosis of Non-small cell lung cancer from peripheral blood gene expression. Cancer Research, 69:9202-10, 2009.
24. 2008 "Endothelial Targeting of Semi-permeable Polymer Nanocarriers for Enzyme Therapies." Biomaterials 29:215-27, 2008.
25. 2008 Variation in the MYLK Gene is Associated with Development of Acute Lung Injury Following Major Trauma, Critical Care Medicine, 36:2794-800, 2008.
26. 2008 B Cell Depletion Using an anti-CD20 Antibody Augments Anti-tumor Immune Responses and Immunotherapy in Murine Models. Journal of Immunotherapy, 31: 446-457, 2008.
27. 2008 TGF-b receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid tumors. Clin. Cancer Res., 14: 3966-3974, 2008.
28. 2008 Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells PLoS ONE. 2008 Sep 26;3(9):e3289.
29. 2008 Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes J Control Release. 2008, 130:226-33.
30. 2008 Systemic Blockade of Transforming Growth Factor-b Signaling Augments the Efficacy of Immunogene Therapy. Cancer Research, 68:10247-10256, 2008.
31. 2008 Malignant Mesothelioma. In Pulmonary Diseases and Disorders, 4th Edition, Fishman, A.P. (editor), McGraw-Hill, New York, 2008.
32. 2008 Gene Therapy for Pleural Diseases. In Pleural Diseases: An International Textbook. Richard Light and Y.C. Gary Lee, Editors. Arnold Publishers, London., 2008
33. 2008 Soluble Type II Transforming Growth Factor-b Receptor Inhibits Tumorigenesis by Augmenting Host Anti-tumor Immunity. In Transforming Growth Factor-beta in Cancer Therapy, Editor, Sonia Jakowlew, Ph.D., in Dr. B. Teicher’s “Methods in Molecular Biology” series on “Cancer Drug Discovery and Development”, pp 697-706, 2008, Humana Press
34. 2008 RhoA activation and actin reorganization involved in endothelial CAM-mediated endocytosis of anti-PECAM carriers: critical role for tyrosine 686 in the cytoplasmic tail of PECAM-1 Blood, 111:3024-3033, 2008.
35. 2007 Ostrand-Rosenberg, S. Cross-talk between Myeloid-derived Suppressor Cells and Macrophages Subverts Tumor Immunity towards a Type-2 Responses J. Immunol., 179:977-83, 2007.
36. 2007 Identification of 10 Gene Classifier for Head and Neck Squamous Cell Carcinoma and Lung Squamous Cell Carcinoma: Towards a Distinction between Primary and Metastatic Squamous Cell Carcinoma of the Lung Clinical Cancer Research, 13:2905-2915, 2007.
37. 2007 PECAM-1 directed endothelial targeting of superoxide dismutase alleviates oxidative stress caused by either extracellular or intracellular superoxide. J. of Pharmacology and Experimental Therapeutics. 323:450-7, 2007.
38. 2007 Cytokine gene therapy for malignant pleural mesothelioma. J. of Thoracic Oncology. 2: 2007.
39. 2007 Prophylactic thrombolysis by thrombin-activated latent pro-urokinase targeted to PECAM-1 in the pulmonary vasculature Blood, 111:1999-2006; 2007
40. 2007 Gemcitabine Has Significant Immunomodulatory Activity in Murine Tumor Models Independent of its Cytotoxic Effects Cancer Biology and Therapy; 6:880-5, 2007.
41. 2007 A Phase I Clinical Trial of Single-Dose Intrapleural Interferon-Beta Gene Transfer For Malignant Mesothelioma and Metastatic Pleural Effusions: High Rate of Anti-Tumor Immune Responses Clinical Cancer Research, 13:4456-4466, 2007.
42. 2007 The Vascular Disrupting Agent, 5,6 Di-methylxanthenone-4-acetic Acid (DMXAA), Directly Activates Dendritic Cells Through a MyD88-indpendent Mechanism and Generates Anti-Tumor Cytotoxic T-Lymphocytes. Cancer Research, 67:7011-7019, 2007
43. 2007 A Novel Small Molecule Inhibitor of TGF-beta type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth in vivo and Prevents the Extent of Tumor Recurrence After Surgical Resection Cancer Research, 67:2351-2359, 2007.
44. 2007 Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium J. Controlled Release, 118:235-244, 2007
45. 2006 Cyclooxygenase-2 Inhibition augments efficacy of a cancer vaccine. Clinical Cancer Research, 12:214-222, 2006.
46. 2006 Blockade of TNFa Decreases Both Inflammation and Efficacy of Intrapulmonary Ad.IFN Beta Immunotherapy in an Orthotopic Model of Bronchogenic Lung Cancer Molecular Therapy, 13:910-917, 2006.
47. 2006 Interferon-beta adenoviral gene therapy in a patient with ovarian cancer. Nature Clinical Oncology, 3:633-639, 2006.
48. 2006 Synthesis of the stable isotope labeled antiviral nucleoside analog [8-13C-7,9-15N2]-ganciclovir. Journal of Labelled Compounds and Radiopharmaceuticals, 49:1131-1139, 2006.
49. 2006 Dissociation between alvelolar transmigration of neutrophils and lung injury in hyperoxia. Am J Physiol Lung Cell Mol Physiol. 291(5):L1050-1058, 2006.
50. 2005 Prognostic implications of cell cycle, aopoptosis, and angiogenesis biomarkers in non-small cell lung cancer Clin Cancer Res. 11:3974-3986, 2005.
51. 2005 Gene Therapy Malignant Mesothelioma. Springer-Verlag New York, Inc., Harvey I. Pass, Nicholas J. Vogelzang, and Michele Carbone, eds., pp. 778-820, 2005.
52. 2005 Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with pro-urokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood,106:4191-4198, 2005.
53. 2005 Activated Tumor-Associated Macrophages and CD8+ T-cells are the Key Mediators of Anti-tumor Effects of the Vascular Disrupting Agent 5,6 Di-methylxanthenone-4-acetic Acid (DMXAA) in Murine Models of Lung Cancer and Mesothelioma” Cancer Research, 65:11752-11761, 2005.
54. 2005 Intrapulmonary interferon-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of lung adenocarcinoma via a combination of direct toxicity, NK cell, and CD8 T-cell mediated effects Cancer Research, 65:8379-8387, 2005.
55. 2005 Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances anti-tumor immune activity. Clinical Cancer Research, 11:6713-6721, 2005.
56. 2005 Long-Term Follow-up of Patients with Malignant Pleural Mesothelioma Receiving High Dose Adenovirus Herpes Simplex Thymidine kinase (HSVtk)/ Ganciclovir (GCV) Suicide Gene Therapy Clinical Cancer Research, 11:7444-7453, 2005.
57. 2005 Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma Cancer Biology and Therapy, . 4; 342-346, 2005.
58. 2005 Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor, Rofecoxib: Potential value as adjuvant therapy after surgery Annals of Surgery. 241:168-178, 2005
59. 2004 Role for platelet-endothelial cell adhesion molecule-1 (PECAM) in macrophage Fcg receptor function. Am. J. Resp Cell Molec Biol., 31:246-255, 2004.
60. 2004 Soluble Type II Transforming Growth Factor-b Receptor Inhibits Both Small and Large Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Anti-tumor Immunity. Clinical Cancer Research, 10:5907-5918, 2004.
61. 2004 Gene Therapy In Pleural Diseases In Derrame Pleural (Pleural Effusions). Francisco S. Vargas, Evaldo Marchi and Lisete R. Teixeira, Editors. Roca Publisher Limited, São Paulo, Brazil, pp. 607-620, 2004.
62. 2004 TNFerade to the Rescue? Guidelines for Evaluating Phase I Cancer Gene Transfer Trials. J. Clin. Oncol., 22:577-579, 2004.
63. 2004 Role of lateral cell-cell border location and extracellular/transmembrane domains in PECAM/CD31 mechanosensation- Biochemical and Biophysical Research Communications. Research Communications. 320(4):1076-81, 2004.
64. 2004 Immunogene therapy with interferon-b before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma. Cancer Biology and Therapy, 2:383-394, 2003.
65. 2003 Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling Cancer Biology and Therapy, 2:291-298, 2003.
66. 2003 Antibody-directed targeting of catalase to the endothelial antigen PECAM augments pulmonary antioxidant defense in vivo Am. J. Physiol.: Lung Cell Mol. Physiol., 285: L283-292, 2003
67. 2003 Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury Nature Biotechnology, 21:392-398, 2003
68. 2003 ICAM-directed vascular immunotargeting of drugs to the endothelial luminal surface Blood, 101:3977-3984, 2003.
69. 2003 PECAM-1 in neutrophil emigration during acute bacterial pneumonia in mice and rats. Am. J. Resp. Crit. Care Med, 167:164-170, 2003
70. 2003 Adenovirus-mediated gene transfer of enhanced herpes simplex thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Therapy, 10:353-364, 2003.
71. 2003 PECAM-1-dependent neutrophil transmigration is independent of monolayer PECAM-1 signaling or localization Blood, 101:2816-2825, 2003.
72. 2003 Gene Expression Profiling of the Early Pulmonary Response to Hyperoxia in Mice Am. J. Resp. Cell and Molecular Biology, 28:682-696, 2003
73. 2003 Gene Therapy for Pleural Diseases In Pleural Diseases: An International Textbook. Richard Light and Y.C. Gary Lee, Editors. Arnold Publishers, London., pp526-541, 2003.
74. 2003 Gene Therapy for Malignant Pleural Mesothelioma Malignant Mesothelioma, Kenneth O’Byrne and Hedy Kindler, eds., Oxford University Press, 2003.
75. 2003 Gene expression profiling of malignant mesothelioma Clin. Cancer Research, 9, 3080-3097, 2003.
76. 2003 Microarray data simulator for improved selection of differentially expressed genes Cancer Biology and Therapy, 2:383-394, 2003.
77. 2003 se of cycloxygenase-2 inhibition to enhance the efficacy of immunotherapy Cancer Research, 63:7845-7852, 2003.
78. 2003 Differentially expressed apoptotic genes in early stage lung adenocarcinoma predicted by expression profiling. Cancer Biology and Therapy, 2:566-571, 2003.
79. 2003 A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci. 116::1599-1609, 2003
80. 2003 PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosis. Blood, 102:169-179, 2003.
81. 2002 BRAF and RAS mutations in human lung cancer and melanoma. Cancer Research, 62:6997-7000, 2002.
82. 2002 PECAM-1 (CD31) regulates a hydrogen peroxide-activated nonselective cation channel in endothelial cells. J. Cell Biol., 157:173-184, 2002.
83. 2002 Changes in plasma gelsolin concentration during acute oxidant lung injury in mice. Lung, 180:91-104, 2002.
84. 2002 Replication selective herpes simplex virus-1 mutant therapy of cervical cancer is enhanced by low dose radiation Human Gene Therapy, 13(5):627-39, 2002
85. 2002 Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. J. Cellular Biochemistry, 84, 455-459, 2002.
86. 2002 PECAM-directed immunotargeting to the cardiopulmonary vasculature. J. Pharm. Exp. Therapeutics, 300:777-786, 2002.
87. 2002 A murine model of acute lung injury induced by thrombomodulin-directed immunotargeting of a hydrogen peroxide-generating enzyme to pulmonary endothelium. Am. J. Pathol., 160:1155-1169, 2002.
88. 2002 PECAM-mediated intracellular immunotargeting is controlled by particle size. Blood, 99:912-922, 2002
89. 2002 Gene Therapy in Lung Disease Steven M. Albelda, Editor. Marcel Decker, Inc. New York, 2002 [part of the Lung Biology in Health and Disease Series]
90. 2002 Treatment of mesothelioma using adenoviral-mediated delivery of herpes simplex virus thymidine kinase gene in combination with ganciclovir In Gene Therapy of Cancer (second edition). Lattime, E.C. and Gerson, S.L., editors. Academic Press, San Diego, pp. 493-501, 2002.
91. 2002 Gene Therapy of Lung Neoplasms In Clinics in Chest Medicine Mathay, R. Editor, W.B. Saunders Company, Phil, PA, , Vol 23, p265-277, 2002,.
92. 2002 Pulmonary Genetics, Genomics, and Gene Therapy Chest, 121 (supplement), pp 105S-110S, 2002.
93. 2002 Analysis of the immunological response generated by Ad.IFN-b during successful peritoneal tumor gene therapy. Mol. Therapy, 6:210-218, 2002.
94. 2001 PECAM-1 (CD31) engagement activates a phosphoinositide-independent, nonspecific cation channel in endothelial cells. FASEB J., 1257-1260, 2001.
95. 2001 Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment anti-tumor efficiency. Gene Therapy, 8:946-953, 2001.
96. 2001 Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy due to induction of systemic immunity. Cancer Research, 61:6201-6212, 2001.
97. 2001 Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J. Nuclear Medicine, 42:1412-1417, 2001.
98. 2001 Cell-selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting. FASEB J., 15:416-426, 2001.
99. 2000 Antibodies against the first Ig-like domain of human PECAM-1 that inhibit PECAM-1-dependent homophilic adhesion block in vivo neutrophil recruitment J. Immunol., 164:452-462, 2000
100. 2000 Functional genomics and expression profiling: Be there or be square Am J Respir Cell Mol Biol. 23:265-9, 2000.
101. 2000 A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Therapy, 7:1511-1518, 2000.
102. 2000 Effect of pre-existing anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model. Molecular Therapy, 2:387-93, 2000.
103. 2000 Efficacy of repeated adenoviral suicide gene therapy in a localized murine tumor model. Annals of Thoracic Surgery, 70, 1856-1870, 2000.
104. 2000 Cationic lipid:bacterial DNA complexes elicit anti-tumor effects and adaptive immunity in murine intraperitoneal tumor models Cancer Research, 60, 2955-2963, 2000.
105. 2000 Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Therapy, 7:275-283, 2000.
106. 2000 Contributions of the extracellular and cytoplasmic domains of platelet-endothelial cell adhesion molecule-1 (PECAM/CD31) in regulating cell-cell localization. J. Cell Science, 113:1459-1469, 2000
107. 2000 Recent advances in molecular biological techniques and their relevance to pulmonary research. Thorax, 55:329-339, 2000.
108. 2000 Gene therapy for lung disease: Hype or Hope? Annals of Internal Medicine, 132:649-660, 2000.
109. 2000 Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer Clinical Cancer Research,. 2000 Aug;6(8):3342-53
110. 2000 Immunotargeting of glucose oxidase to endothelium in vivo causes oxidative vascular injury in the lungs. Am. J. Physiology (Lung Cell. Mol. Physiol.)., 278:L794-805, 2000.
111. 2000 A rapid and sensitive method for the quantification of ganciclovir in plasma using liquid chromatography/selected reaction monitoring/mass spectrometry.   Biomed Chromatogr. 2000 Apr;14(2):93-8..
112. 1999 Cadherin and cateninin expression in normal human bronchial epithelium and non-small cell cancer. Lung Cancer, 24:157-168, 1999.
113. 1999 The prognostic value of FDG-PET imaging in malignant pleural mesothelioma J. Nuclear Medicine, 40:1241-1245, 1999.
114. 1999 Treatment of malignant mesothelioma Chest, 116:504-520, 1999.
115. 1999 Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clinical Cancer Research, 5:1523-1537, 1999.
116. 1999 The evaluation of adenoviral p53-mediated bystander effect in gene therapy for cancer. Cancer Gene Therapy, 6:291-301, 1999
117. 1999 Evaluation of an E1/E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Human Gene Therapy, 10:463-475, 1999.
118. 1999 Streptavadin facilitates internalization and pulmonary targeting of an anti-endothelial cell antibody (PECAM-1): A novel strategy for intra-endothelial drug delivery Proc. Natl. Acad. Sci., USA, 96:2379-2384, 1999.
119. 1999 Adenoviral Gene Therapy for Malignant Pleural Mesothelioma In Adenoviruses: Basic Biology to Gene Therapy. Seth, P. Editor; R.G. Landes Company, Georgetown, TX, pp. 305-312, 1999.
120. 1999 Immunotargeting of glucose oxidase to endothelial cells induces intracellular generation of hydrogen peroxide and oxidative stress. Am. J. Physiology (Lung Cell. Mol. Physiol.). 21:L271-281, 1999.
121. 1999 Progression-related expression of beta3 integrin in melanomas and nevi. Human Pathology, 30:562-7, 1999
122. 1999 Protamine increases the in vivo efficacy of adenoviral-mediated gene transfer without improving treatment efficacy in animal tumor models. Gene Therapy, 6: in 1600-1610 , 1999.
123. 1998 Impact of pre-existing and induced humoral and cellular immune responses in an adenoviral-based gene therapy Phase 1 clinical trial for localized malignancy Human Gene Therapy, 9: 2121-2133, 1998.
124. 1998 Metabolic imaging of malignant pleural mesothelioma with fluorine-18-deoxyglucose postion emission tomography Chest, 114:713-722, 1998.
125. 1998 Regulation of PECAM-1 tyrosine phosphorylation by the Src and Csk families of tyrosine protein kinases J. Biol. Chem., 273:15765-15762, 1998.
126. 1998 CD40-mediated signal transduction in human airway smooth muscle J. Immunol., 161:3120-3127, 1998.
127. 1998 Human hair follicle stem cells preferentially express cytokeratin 15 and reside in the hair follicle bulge. J. Cell Science, 111:3179-3188, 1998.
128. 1998 In vivo and in vitro expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) in human trophoblasts. Molecular Human Reproduction, 4:357-367, 1998.
129. 1998 . PECAM-1 (CD31). In Guidebook to the Extracellular Matrix and Adhesion Proteins, Kreis, T., Vale, R. (editors), Oxford University Press, London, England, Second Edition, 1998, pp 165-167
130. 1998 Gene Therapy for Malignant Mesothelioma Hematological/Oncological Clinics of North America, 12:553-568, 1998.
131. 1998 Gene Therapy for Malignant Mesothelioma Sourcebook on Asbestos Diseases, Peters, G. and Peters. B.J., Editors, Lexis Publishing, Charlottesville, VA.,Vol 18:329-351 1998.
132. 1998 The function of cell adhesion molecules in lung inflammation: More questions than answers Am. J. Resp. Cell Molec. Biol., 19:533-536, 1998.
133. 1998 Engagement of PECAM-1 on human endothelial cells increases intracellular calcium ion concentration and stimulates prostacyclin release. J. Clin. Invest., 101; 212-222, 1998.
134. 1998 Adenovirus-mediated herpes simplex virus thymidine kinase gene delivery in patients with localized malignancy: Results of a phase 1 clinical trial in malignant mesothelioma Human Gene Therapy, 9:1083-1092, 1998
135. 1997 Experimental production and modulation of human cytotoxic dermatitis in human-murine chimeras Am. J. Pathol. 150:631-639, 1997.
136. 1997 Cell Adhesion Molecules in Asthma In Asthma, Barnes, PJ., Grunstein, M.M., Leff, A., Woolcock (editors), Raven Press, New York, 523-533, 1997.
137. 1997 Malignant Mesothelioma In Pulmonary Diseases and Disorders, 3rd Edition, Fishman, A.P. (editor), McGraw-Hill, New York, 1997.
138. 1997 Gene transfer and thoracic surgery: more to come. Annals of Thoracic Surgery. 63(6):1527-1528, 1997.
139. 1997 Loss of av integrin expression and recurrence in node-negative lung carcinoma. Ann. Thorac. Surg. 64:949-953, 1997.
140. 1997 The in vivo and in vitro characterization of an engineered human antibody to E-selectin. Immunotechnology 3: 107-116, 1997.
141. 1997 Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy. Gene Therapy, 4:909-917, 1997.
142. 1997 Novel cytokine-independent induction of endothelial adhesion molecules regulated by PECAM-1 (CD31). Cell Biol., 139:219-228, 1997.
143. 1997 The tyrosine residue in exon 14 of the cytoplasmic domain of Platelet-Endothelial Cell Adhesion Molecule-1 (PECAM-1 /CD31) regulates ligand binding specificity Cell Biol.,138:1425-1435, 1997.
144. 1997 Expression and function of endothelial cell av-integrin receptors in wound-induced human angiogenesis in human skin/SCID mouse chimeras. Am. J. Pathol., 151:975-983, 1997.
145. 1997 PECAM-1/CD31 - A multifunctional vascular cell adhesion molecule. Trends in Cardiovascular Medicine, 151:671-677, 1997.
146. 1997 Involvement of endothelial PECAM-1/CD31 in angiogenesis Am. J. Pathol., 671-677, 1997.
147. 1997 Human skin/SCID mouse chimeras as an in vivo model to study human cutaneous mastocytosis. J. Invest. Dermatology, 109:102-107, 1997.
148. 1997 The effect of promoter strength in adenoviral vectors containing herpes simplex thymidine kinase on cancer gene therapy in vitro and in vivo Cancer Gene Therapy, 4:213-221, 1997.
149. 1997 Expression of integrin cell adhesion receptors during human airway epithelial repair in vivo: Upregulation of av integrins and implications for adenovirus infection Am. J. Physiology (Lung Cell. Mol. Physiol.,17): L256-263 1997.
150. 1997 Use of a “replication restricted” Herpes virus to treat localized human malignancy. Ca. Research, 57:466-471, 1997.
151. 1996 Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase cDNA followed by ganciclovir therapy in non-human primates Hum. Gene Therapy, 7:2225-2233, 1996.
152. 1996 Herpes simplex 1716- an ICP 34.5 Mutant- is severely replication restricted in human skin xenografts in vivo. Virology, 223:392-395, 1996.
153. 1996 DeLisser, H.M. PECAM-1 homophilic adhesion is mediated by Ig-like domains 1 and 2 and depends on the cytoplasmic domain and the level of surface expression. J. Biol. Chem., 271: 18561-18570, 1996.
154. 1996 Treatment of advanced mesothelioma with the recombinant adenovirus H5.01RSVTK: A phase 1 trial Human Gene Therapy, 7:2047-2057, 1996.
155. 1996 An anti-PECAM-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane J. Exp. Med., 184:229-239, 1996.
156. 1996 Individually distinct Ig-homology domains in PECAM-1 regulate homophilic binding and modulate receptor affinity J. Biol. Chem. 271:11090-11098, 1996.
157. 1996 Blockade of platelet endothelial adhesion molecule-1 (PECAM-1) protects against myocardial ischemia and reperfusion injury in cats. Immunol., 156:3550-3557, 1996.
158. 1996 The role of selectins and CD18 in leukotriene B4-mediated white blood cell transmigration in human skin grafts transplanted on SCID mice Cell Adhesion and Communication, 3:475-486, 1996.
159. 1996 Gap junctions play a role in the “bystander effect” of the Herpes Simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy, 3:85-92, 1996.
160. 1996 Induction of E-selectin-dependent leukocyte recruitment by mast cell degranulation in human skin grafts transplanted on SCID mice Am. J. Path.,148:177-188, 1996.
161. 1996 Gene therapy approaches for inherited and acquired diseases of the lung. Am. J. Resp. Cell Molec. Biol., 14:1-18, 1996.
162. 1996 Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the HSV-thymidine kinase gene Human Gene Therapy, 7:141-148, 1996.
163. 1996 Treatment of Malignant Mesothelioma In UpToDate in Pulmonary and Critical Care Medicine (CD-ROM Program), Burton Rose, (Editor), UpToDate, Wellesley, MA, 1996.
164. 1995 Cell Adhesion Molecules in Asthma: Homing, Activation, and Airway Remodeling. Am. J. Resp. Cell Molec. Biol., 12;1-3, 1995.
165. 1995 Ligation of the endothelial avb3 integrin increases capillary hydraulic conductivity of rat lung. Circ. Res., 77:651-659, 1995.
166. 1995 Alternative splicing of a specific cytoplasmic exon alters the binding characteristics of murine PECAM-1. J. Biol. Chem., 270: 23672-23680, 1995.
167. 1995 The role of immune suppression in the efficacy of cancer gene therapy utilizing adenovirus transfer of the herpes simplex-thymidine kinase gene Annals of Surgery, 122: 298-310, 1995.
168. 1995 Pleural-based mesothelioma in immune competent rats: A model to study adenoviral gene transfer Annals of Thoracic Surgery, 60:593-598, 1995.
169. 1995 Expression of the b6 integrin in development, inflammation, wound healing, and neoplasia suggest a role in epithelial remodeling. J. Cell Science, 108: 2241-2251, 1995.
170. 1995 Integrin expression in non-small cell carcinoma of the lung. Cancer and Metastasis Reviews, 14: 229-239, 1995.
171. 1995 Gene therapy using adenovirus carrying the herpes simplex thymidine kinase gene to treat in vitro models of human malignant mesothelioma and lung cancer Am. J. Resp. Cell Molec. Biol., 13:7-16, 1995.
172. 1995 Successful treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex-thymidine kinase gene. Annals of Surgery, 222:78-86, 1995.
173. 1995 Distribution and efficiency of adenovirus-mediated gene transfer to human bronchus using xenografts Am. J. Physiology (268): Lung, Cell and Molecular Physiol., 12, L657-665, 1995
174. 1995 Modulation of adhesion molecules by cytokines in vivo using human/SCID mouse chimeras. J. Clin. Immunol.,15: 122S-129S, 1995.
175. 1995 Differential sensitivity of thoracic malignancies to adenovirus-mediated drug sensitization gene therapy J. Thorac. Cardiovasc. Surg., 109:626-631, 1995.
176. 1995 Distribution of integrin cell adhesion molecules in endometrial cancer Am. J. Pathol. 146:717-726, 1995.
177. 1995 Activation of cAMP-dependent pathways in human airway smooth muscle cells inhibits TNFa-induced ICAM-1 and VCAM-1 expression and T-lymphocyte adhesion J. Immunol., 154:2358-2365, 1995.
178. 1995 The Wilms tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am. J. Pathol.,146:344-356, 1995
179. 1995 Localization of multiple functional domains of human PECAM-1 (CD31) by monoclonal antibody epitope mapping Cell Adhesion and Communication,3; 45-66, 1995.
180. 1995 ICAM-1 expression on bronchial epithelium after recombinant adenovirus infection Am. J. Resp. Cell Molec. Biol., 12:142-148, 1995.
181. 1994 Biosynthesis and processing of the cell adhesion molecule PECAM-1 includes production of a soluble form J. Biol. Chem., 269:17183-17191, 1994.
182. 1994 Identification of integrin receptors on cultured human bone cells J. Orthopedic Res., 12:384-394. 1994.
183. 1994 Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg., 57:1395-1401, 1994.
184. 1994 Adhesion molecules and inflammatory injury FASEB J., 8:504-512, 1994.
185. 1994 Use of recombinant adenovirus to transfer the HSV-thymidine kinase gene to thoracic neoplasms: An effective in vitro drug delivery system. Use of recombinant adenovirus to transfer the HSV-thymidine kinase gene to thoracic neoplasms: An effective in vitro drug delivery system.
186. 1994 Radiographic resolution of community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 149:630-635, 1994.
187. 1994 Leukocyte recruitment induced by tumor necrosis factora in human skin is dependent on E-selectin. J. Immunology, 152: 3053-3063, 1994.
188. 1994 Differential expression of the cell adhesion molecules ICAM-1, VCAM-1, and E-selectin in normal and post-transplant myocardium Circulation, 89:1760-1768, 1994.
189. 1994 Deletions in the cytoplasmic domain result in changes in ligand binding properties of PECAM-1. J. Cell Biol., 124: 195-203, 1994.
190. 1994 The integrin cell adhesion molecules. In Cell Adhesion Molecules, Steiner, M. and Richardson, P.D. (editors), CRC Press, 1994 .
191. 1994 Role of cell adhesion molecules in tumor progression and metastasis. In The Handbook of Immunopharmacology: Cell Adhesion Molecules, Wegner, C (editor), Academic Press, London, England,1994 p. 71-88.
192. 1994 Molecular and functional aspects of PECAM-1/CD31 Immunology Today, 15:490-495, 1994.
193. 1994 Platelet-endothelial adhesion molecule-1 (PECAM-1/CD31) and its alternatively spliced isoforms are expressed during early mammalian cardiovascular development Development, 120:2539-2553, 1994.
194. 1994 T Lymphocytes Adhere to Airway Smooth Muscle Cells via Integrins and CD44 and Induce Smooth Muscle Cell DNA Synthesis J. Exp. Med, 180:807-816, 1994.
195. 1994 Expression of endothelial cell adhesion molecules in human bronchial xenografts Am. J. Resp. Crit. Care Med., 150:795-801, 1994.
196. 1993 Maximal migration of human smooth muscle cells on type IV collagen and fibronectin occurs at an intermediate intital attachment strength J. Cell Biol., 122:729-737, 1993.
197. 1993 Growth and invasion of human melanoma in human skin grafted to immunodeficient mice. Am. J. Pathol., 143:528-537, 1993.
198. 1993 PECAM-1 mediates heterophilic glycosaminoglycan-dependent cell-cell adhesion J. Biol. Chem., 258:16307-16046, 1993.
199. 1993 TNFa induces ELAM-1 expression and PECAM-1 (CD31) redistribution in extracutaneous tissues Endothelium, 1:47-54. 1993.
200. 1993 Role of Integrins and other cell adhesion molecules in tumor progression and metastasis Lab Invest., 68:4-17, 1993.
201. 1993 Human/SCID mouse chimeras: an experimental in vivo model system to study the regulation of human endothelial cell-leukocyte adhesion J. Clin. Invest.,91:986-996, 1993.
202. 1993 The distribution of integrin cell adhesion receptors on normal bronchial epithelial cells and lung cancer cells in vitro and in vivo Am. J. Respir. Cell Mol. Biol., 8:562-572, 1993.
203. 1993 CD31 (PECAM-1). In Current Topics in Microbiology and Immunology, Vol. 184: Adhesion in Leukocyte Homing and Differentiation, Dunon, D., Mackay C.R., and Imhof, B.A. (editors), Springer Verlag, Berlin-Heidelberg-New York-Tokyo, 1993, p. 37-45.
204. 1993 PECAM-1 (CD31). In Guidebook to the Extracellular Matrix and Adhesion Proteins, Kreis, T., Vale, R. (editors), Oxford University Press, London, England, 1993, p. 165-166, 1993
205. 1993 Expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1, CD31) during melanoma-induced angiogenesis J. Cutaneous Pathol., 399-406, 1993.
206. 1993 Platelet-endothelial cell adhesion molecule-1 (PECAM-1) is involved in neutrophil recruitment in vivo. Science, 262:1580-1582, 1993.
207. 1993 Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Molecular Biology of the Cell, 4: 973-982, 1993.
208. 1993 Murine platelet endothelial cell adhesion molecule (PECAM-1)/CD31 modulates b2 integrins on lymphocyte-activated killer cells. Eur. J. Immunol., 23: 2464-2471, 1993.
209. 1993 Cell adhesion receptors and early mammalian heart development: an overview Comptes rendus de l’Academie des Sciences, Sciences de la vie/Life Sciences, 316:849-859, 1993.
210. 1993 Regulation of extracellular matrix proteins and integrin cell substratum receptors on epithelium during cutaneous wound healing in vivo Am. J. Pathol., 143: 1458-1469, 1993.
211. 1992 Cytokine-induced expression of transforming growth factor-a and the epidermal growth factor receptor in neonatal skin explants J. Invest. Derm., 99:350-356,1992.
212. 1992 The alveolar capillary barrier in the Adult Respiratory Distress Syndrome In Update: Pulmonary Diseases and Disorders, Fishman, A.P. (editor), McGraw-Hill, New York, 1992, p.197-211.
213. 1992 Differential expression of integrin cell-substratum adhesion receptors on endothelium. In Angiogenesis: Key Principals-Science-Technology-Medicine. Steiner, R., Weisz, P.B., Langer, R. (editors), Birkhausner Verlag, Basil, Switzerland, 1992, p. 188-192.
214. 1992 Life threatening pulmonary hemorrhage. In Principals and Practice of Medical Intensive Care. Carlson, R., Gehab, M. (editors), W.B. Saunders, Philadelphia, 1993, p. 876-882.
215. 1992 Adsorption and elution of extracellular matrix proteins on polystyrene petri dishes: radiolabelling studies with 125I J. Colloid Interface Science. 153:212-225, 1992.
216. 1992 Platelet-endothelial cell adhesion molecule, PECAM-1, modulates cell migration J. Cell Physiol. 153:417-428, 1992.
217. 1992 Association of murine CD31 with transmigrating lymphocytes following antigenic stimulation. Am. J. Pathol., 141:843-854, 1992.
218. 1992 Measurement of individual cell migration parameters for human tissue cells on protein coated-surfaces. Am. Institute of Chemical Engineering J., 38:1092-1104, 1992.
219. 1992 Cellular and Molecular Aspects of PECAM-1 Nouv. Rev. Fr. Hematol., 34[Suppl], S7-S11, 1992
220. 1992 CD31/PECAM-1 is a preferential amplifier of VLA-integrin mediated adhesion for distinctive T-cell subsets J. Exp. Med. 176: 245-253, 1992.
221. 1992 Integrin adhesion molecules in the human endometrium: correlation with the normal and abnormal menstrual cycle . J. Clin. Invest., 90:188-195, 1992.
222. 1992 Identification of cell-substratum adhesion receptors or integrins on cultured rat bone cells. J. Orthopedic Res., 10:766-773,1992.
223. 1992 A heterophilic mechanism for platelet-endothlelial cell adhesion molecule-1 (PECAM-1, CD31) J. Exp. Med., 175:1401-1404, 1992.
224. 1992 The distribution of integrin cell adhesion receptors in normal and malignant lung tissues Am. J. Respir. Cell Mol. Biol., 6:197-206, 1992.
225. 1991 Culture of human adult endothelial cells on liquid-liquid interfaces: A new approach to study cell-matrix interactions In Vitro Cellular & Developmental Biology 27A:525-532, 1991
226. 1991 Endothelial and Epithelial Cell Adhesion Molecules. Am. J. Respir. Cell Mol. Biol. 4: 195-203,1991.
227. 1991 Fluid and solute movement across the alveolar capillary membrane. In Basic Mechanisms of Pediatric Respiratory Disease: Cellular and Integrative Chernick, V., Mellins, R. (editors), B.C. Decker, Inc., Philadelphia, 1991, pp. 188-202.
228. 1991 Cytoplasmic domains of integrin b1 and b3 subunits are functionally interchangeable J. Cell Biol., 114:1079-1088, 1991.
229. 1991 Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule. J. Cell Biol. 114:1059-1068, 1991.
230. 1990 EndoCAM: A novel endothelial cell-cell adhesion molecule J. Cell Biol. 110: 1227-1237, 1990.
231. 1990 Integrins and other cell adhesion molecules FASEB J.,4:2868-2880, 1990.
232. 1990 Spatiotemporal segregation of endothelial cell integrin and non-integrin extracellular matrix-binding proteins during adhesion events. J. Cell Biol. 110: 789-801, 1990.
233. 1990 Role of growth factors in pulmonary hypertension. In The Pulmonary Circulation. Normal and Abnormal Fishman, A.P. (editor), University of Pennsylvania Press, Philadelphia, 1990, pp 201-216.
234. 1990 Immunohistochemical and molecular analysis of b1 and b3 integrins Cell Differentiation and Development 32:189-202, 1990.
235. 1990 Integrin distribution in malignant melanoma: Association of the b3 subunit with tumor progression. Cancer Research, 50: 6757-6744, 1990.
236. 1989 Pulmonary extraction of propranolol in normal and oxygen-toxic sheep Journal of Pharmacology and Experimental Therapeutics 250: 93-99, 1989.
237. 1989 Identification and characterization of cell-substratum adhesion receptors on cultured human large vessel endothelial cells J. Clin. Invest. 83: 1992-2002, 1989.
238. 1989 Endotoxin stimulates platelet-derived growth factor production from cultured human pulmonary endothelial cells. Am. J. Physiol. (Lung Cell. Mol. Physiol. 1) 257: L65-L70, 1989.
239. 1988 Severe hemoptysis associated with pulmonary aspergilloma-percutaneous treatment with amphotericin B and N-acetylcysteine Chest 94: 1225-1231, 1988.
240. 1988 Aspergillosis. In Pulmonary Diseases and Disorders, 2nd Edition, Fishman, A.P. (editor), McGraw-Hill, New York, 1988, pp. 1639-1656.
241. 1988 Characterization of beta adrenergic receptors in cultured human and bovine endothelial cells J. Appl. Physiol. 65: 1251-1257, 1988.
242. 1988 The permeability characteristics of cultured endothelial cell monolayers. J. Appl. Physiol. 64: 308-322, 1988.
243. 1987 Brief Review: Perspectives in Endothelial Cell Biology Appl. Physiol. 62: 1345-1348, 1987.
244. 1987 Tuberculous pleural effusions. Chest 91: 106-109, 1987.
245. 1986 Non-tuberculous mycobacterial infection in the acquired immunodeficiency syndrome: clinical, pathologic and radiographic features Radiology 160: 77-82, 1986
246. 1986 Effect of increased ventilation on lung lymph flow in anesthetized sheep. J. Appl. Physiol. 60: 2063-2070, 1986.
247. 1985 Treatment of Sarcoidosis. In Current Therapy in Allergy, Immunology, and Rheumatology Fauci, A.S., and Lichtenstein, L.M. (editors), B.C. Decker Inc., Philadelphia, 1985, pp. 120-125.
248. 1985 Diffuse pulmonary hemorrhage: a review and classification Radiology 154: 289-297, 1985.
249. 1985 The expanding spectrum of pulmonary disease caused by non-tuberculosis myobacteria Radiology 157: 289-296, 1985.
250. 1985 Role of high frequency jet ventilation (HFJV) in the treatment of bronchopleural fistulae (BPF). Anesthesiology 63: 551-554, 1985.
251. 1985 Observations on the significance of the air crescent in massive pulmonary aspergillosis Radiology 157: 605-610, 1985.
252. 1985 Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis: influence of bone marrow recovery in patients with acute leukemia. Am. Rev. Respir. Dis. 131: 115-120, 1985.
253. 1984 The role of fiberoptic bronchoscopy in the diagnosis of invasive pulmonary aspergillosis in patients with acute leukemia Am. J. Med. 76: 1027-1034, 1984.
254. 1984 The diagnostic utility of pleural fluid eosinophilia Am. J. Med. 77: 915-920, 1984.
255. 1983 Ventilator-induced subpleural air cysts: clinical, radiographic and pathologic significance Am. Rev. Respir. Dis. 127: 360-365, 1983. [Also published in 1984 Yearbook of Critical Care, M. Rogers (ed.), Yearbook Medical Publishers, Chicago, 1984, pp. 243-245 and Pulmonary Disease Reviews Volume V., 1984].
256. 1982 Bronchopleural fistula complicating invasive aspergillosis Am. Rev. Respir. Dis. 126: 163-165, 1982.
257. 1982 Pleural thickening: its significance and relationship to asbestos dust exposure Am. Rev. Respir. Dis. 126: 621-624, 1982.
258. 1979 Ventricular tachycardia terminated by carotid sinus massage Pace 2: 603-607, 1979.
259. 1976 Intracranial cyclohexamide: effect on male mouse sexual behavior and plasma testosterone. Pharmacology, Biochemistry and Behavior. 4: 185198, 1976.
260. 1976 Inhibition of the ejaculatory reflex in B6D2F1 mice by testosterone propionate Behavioral Biology 16: 378-378, 1976. [Also published in Reading in Animal Behavior. 3rd Edition, T. McGill, ed. Holt, Reinhart and Winston, p. 172-177, 1977]
261. 1975 Examination of plasma testosterone levels in B6D2F1 Mice Senior Honor Thesis, Williams College, 1975.


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.